Alexander Y. Walley, MD

Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr Walley is Professor of Medicine and an addiction expert at Boston Medical Center and Chobanian and Avedisian School of Medicine focused on the medical complications of substance use, specifically HIV and overdose. Dr Walley has conducted multiple studies related to the opioid crisis and the integration of addiction specialty care and general medical care. He has served as PI on a CDC-SAMHSA-Epi-AID investigation of the surge in fentanyl-related overdose, a CDC-funded study of the Massachusetts community naloxone program which demonstrated community-level reductions in overdose death rates, and a SAMHSA-funded program that integrated addiction treatment into the clinical care of people with/at risk for HIV. He is principal investigator for CDC and NIH funded studies of community overdose interventions. For the NIH-funded HEALing Communities Study - Massachusetts, he served as the Care Continuum Core Director 2019-2025. He has worked as Co-I with addiction, overdose, and HIV expertise on NIDA and NIAAA-funded clinical trials and cohort studies.

Dr. Walley is a founding director of the Grayken Addiction Medicine Fellowship. From 2011 to 2022, 20 addiction specialists graduated, 6 of whom serve as directors for addiction medicine fellowships, 13 are faculty at medical schools, 9 at Boston University School of Medicine. He was a founding board member and treasurer of the Addiction Medicine Fellowship Director’s Association 2016-2019 and American College of Academic Addiction Medicine (ACAAM) starting in 2019. He is currently the president for ACAAM for 2023-2025. With his mentor, Dr. Jeffrey Samet, he is multi-PI on the NIDA-funded R25 Clinical Addiction Research and Education Program, which supports the Chief Resident and Fellow Immersion Training and the CARE Faculty Scholar programs.

Dr. Walley provides primary care and addiction medicine consultations in the HIV primary care clinic at Chobanian and Avedisian School of Medicine/BMC. He founded BMC’s inpatient Addiction Consult Service in 2015 and the Faster Paths low-barrier access substance use clinic in 2016. He previously was a site medical director for opioid treatment programs in Boston from 2007 to 2016. He serves as the medical director for the Massachusetts Department of Public Health’s Bureau of Substance Addiction Services, the Overdose Prevention Program, and the SafeSpot Overdose Prevention Hotline. Since 2007, the MDPH program has trained and equipped over 100,000 people in Massachusetts’s communities with naloxone rescue kits, including people at-risk for overdose and their social networks.

Publications

  • Published 4/3/2025

    Jayasinghe T, Drainoni ML, Walley A, Grella C, Majeski A, Rolles A, Cogan A, Venkatesan G, Stein MD, Larochelle M, Samet JH, Kimmel SD. "Every Time I Go in There, It Gives Me Time to Reflect": A Qualitative Study of Patient Perspectives on Substance Use, Medications for Opioid Use Disorder, and Harm Reduction Following Hospitalization for Serious Injection-Related Infection. Open Forum Infect Dis. 2025 May; 12(5):ofaf201. PMID: 40352630.

    Read at: PubMed

  • Published 4/1/2025

    Stopka TJ, Dalvi N, Young LD, Shrestha S, Valerio DD, Walley AY. Trends in Extended-Release and Non-Extended-Release Buprenorphine Dispensing. JAMA Netw Open. 2025 Apr 01; 8(4):e253158. PMID: 40184073.

    Read at: PubMed

  • Published 3/19/2025

    Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Mar 19. PMID: 40104887.

    Read at: PubMed

  • Published 2/5/2025

    McCann NC, Yan S, McMahan VM, Pope E, Rolles A, Brennan S, Marti XL, Kosakowski S, Coffin PO, Walley AY. Test-Retest Reliability of a Timeline Follow-back Method to Assess Opioid Use and Treatment. J Addict Med. 2025 Feb 05. PMID: 39908533.

    Read at: PubMed

  • Published 1/23/2025

    Zaragoza S, Silcox J, Rapisarda S, Summers C, Case P, To C, Chatterjee A, Walley AY, Komaromy M, Green TC. Developing a comprehensive inventory to define harm reduction housing. Harm Reduct J. 2025 Jan 23; 22(1):11. PMID: 39849487.

    Read at: PubMed

Other Positions

  • Member, Evans Center for Interdisciplinary Biomedical Research
    Boston University
  • Faculty, Medicine
    Boston University Chobanian & Avedisian School of Medicine
  • Courtesy Staff Privileges, Medicine
    Boston Medical Center

Education

  • Johns Hopkins University School of Medicine, MD
  • Boston University School of Public Health, MSc
  • Harvard College, AB